Is CervoMed Inc. (CRVO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 102.3% / 30% | 5.9% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 102.3% / 33% | 5.9% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 90.3% / 33% | 5.2% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 102.3% / 33% | 5.9% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 90.3% / 33% | 5.2% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -95479.2% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -93.9% | |
| Return on Assets (ROA) | -53.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$23M |
| Free Cash Flow | -$23M |
| Current Ratio | 4.9 |
| Total Assets | $23M |
Price & Trading
| Last Close | $3.92 |
| 50-Day MA | $4.84 |
| 200-Day MA | $7.32 |
| Avg Volume | 89K |
| Beta | -5.9 |
|
52-Week Range
$3.58
| |
About CervoMed Inc. (CRVO)
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is CervoMed Inc. (CRVO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), CervoMed Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is CervoMed Inc.'s debt ratio?
CervoMed Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are CervoMed Inc.'s key financial metrics?
CervoMed Inc. has a market capitalization of $34M. Return on equity stands at -93.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.